Microbot Medical Inc. (NASDAQ: MBOT) Stock Competitors & Peer Comparison
See MBOT's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for MBOT and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MBOT | $1.09 | +4.81% | 73.2M | -4.54 | -$0.24 | N/A |
| ABT | $109.40 | -0.69% | 189.3B | 21.00 | $5.21 | +2.30% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| MDT | $98.88 | -0.41% | 126.5B | 17.88 | $5.53 | +2.89% |
| SYK | $310.55 | +1.22% | 119.1B | 23.19 | $13.39 | +1.14% |
| BSX | $43.50 | -1.85% | 63B | 14.03 | $3.10 | N/A |
| EW | $95.19 | +2.07% | 54.9B | 35.26 | $2.70 | N/A |
| GEHC | $80.66 | +1.40% | 36.5B | 16.46 | $4.90 | +0.18% |
| DXCM | $82.97 | -2.11% | 30.9B | 32.54 | $2.55 | N/A |
| PHG | $28.46 | +3.15% | 27.5B | 16.27 | $1.75 | +3.46% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
MBOT vs ABT Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, ABT has a market cap of 189.3B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while ABT trades at $109.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas ABT's P/E ratio is 21.00. In terms of profitability, MBOT's ROE is -0.22%, compared to ABT's ROE of +0.09%. Regarding short-term risk, MBOT is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
MBOT vs BSX-PA Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, MBOT's ROE is -0.22%, compared to BSX-PA's ROE of +0.14%. Regarding short-term risk, MBOT is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check BSX-PA's competition here
Medtronic Plc (NYSE: MDT)
MBOT vs MDT Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, MDT has a market cap of 126.5B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while MDT trades at $98.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas MDT's P/E ratio is 17.88. In terms of profitability, MBOT's ROE is -0.22%, compared to MDT's ROE of +0.11%. Regarding short-term risk, MBOT is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
MBOT vs SYK Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, SYK has a market cap of 119.1B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while SYK trades at $310.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas SYK's P/E ratio is 23.19. In terms of profitability, MBOT's ROE is -0.22%, compared to SYK's ROE of +0.16%. Regarding short-term risk, MBOT is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
MBOT vs BSX Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, BSX has a market cap of 63B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while BSX trades at $43.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas BSX's P/E ratio is 14.03. In terms of profitability, MBOT's ROE is -0.22%, compared to BSX's ROE of +0.14%. Regarding short-term risk, MBOT is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
MBOT vs EW Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, EW has a market cap of 54.9B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while EW trades at $95.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas EW's P/E ratio is 35.26. In terms of profitability, MBOT's ROE is -0.22%, compared to EW's ROE of +0.10%. Regarding short-term risk, MBOT is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check EW's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
MBOT vs GEHC Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, GEHC has a market cap of 36.5B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while GEHC trades at $80.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas GEHC's P/E ratio is 16.46. In terms of profitability, MBOT's ROE is -0.22%, compared to GEHC's ROE of +0.16%. Regarding short-term risk, MBOT is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check GEHC's competition here
DexCom, Inc. (NASDAQ: DXCM)
MBOT vs DXCM Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, DXCM has a market cap of 30.9B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while DXCM trades at $82.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas DXCM's P/E ratio is 32.54. In terms of profitability, MBOT's ROE is -0.22%, compared to DXCM's ROE of +0.37%. Regarding short-term risk, MBOT is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check DXCM's competition here
Koninklijke Philips N.V. (NYSE: PHG)
MBOT vs PHG Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, PHG has a market cap of 27.5B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while PHG trades at $28.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas PHG's P/E ratio is 16.27. In terms of profitability, MBOT's ROE is -0.22%, compared to PHG's ROE of +0.10%. Regarding short-term risk, MBOT is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
MBOT vs ZBH Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, ZBH has a market cap of 18.5B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while ZBH trades at $97.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas ZBH's P/E ratio is 11.44. In terms of profitability, MBOT's ROE is -0.22%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, MBOT is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
MBOT vs ABMD Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas ABMD's P/E ratio is 65.36. In terms of profitability, MBOT's ROE is -0.22%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, MBOT is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check ABMD's competition here
Glaukos Corporation (NYSE: GKOS)
MBOT vs GKOS Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, GKOS has a market cap of 13.8B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while GKOS trades at $233.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas GKOS's P/E ratio is -270.71. In terms of profitability, MBOT's ROE is -0.22%, compared to GKOS's ROE of -0.25%. Regarding short-term risk, MBOT is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check GKOS's competition here
Smith & Nephew plc (NYSE: SNN)
MBOT vs SNN Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, SNN has a market cap of 12.6B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while SNN trades at $30.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas SNN's P/E ratio is 20.38. In terms of profitability, MBOT's ROE is -0.22%, compared to SNN's ROE of +0.12%. Regarding short-term risk, MBOT is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check SNN's competition here
Penumbra, Inc. (NYSE: PEN)
MBOT vs PEN Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while PEN trades at $320.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas PEN's P/E ratio is 83.53. In terms of profitability, MBOT's ROE is -0.22%, compared to PEN's ROE of +0.10%. Regarding short-term risk, MBOT is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
MBOT vs SWAV Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas SWAV's P/E ratio is 78.76. In terms of profitability, MBOT's ROE is -0.22%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, MBOT is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check SWAV's competition here
Align Technology, Inc. (NASDAQ: ALGN)
MBOT vs ALGN Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, ALGN has a market cap of 10.8B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while ALGN trades at $151.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas ALGN's P/E ratio is 13.82. In terms of profitability, MBOT's ROE is -0.22%, compared to ALGN's ROE of +0.12%. Regarding short-term risk, MBOT is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check ALGN's competition here
Insulet Corp. (NASDAQ: PODD)
MBOT vs PODD Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, PODD has a market cap of 10.7B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while PODD trades at $154.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas PODD's P/E ratio is 26.38. In terms of profitability, MBOT's ROE is -0.22%, compared to PODD's ROE of +0.27%. Regarding short-term risk, MBOT is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check PODD's competition here
Globus Medical, Inc. (NYSE: GMED)
MBOT vs GMED Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, GMED has a market cap of 10.7B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while GMED trades at $79.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas GMED's P/E ratio is 17.92. In terms of profitability, MBOT's ROE is -0.22%, compared to GMED's ROE of +0.12%. Regarding short-term risk, MBOT is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check GMED's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
MBOT vs BIO-B Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, BIO-B has a market cap of 10.1B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while BIO-B trades at $374.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas BIO-B's P/E ratio is -65.96. In terms of profitability, MBOT's ROE is -0.22%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, MBOT is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check BIO-B's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
MBOT vs BIO Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, BIO has a market cap of 10B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while BIO trades at $374.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas BIO's P/E ratio is 40.40. In terms of profitability, MBOT's ROE is -0.22%, compared to BIO's ROE of +0.03%. Regarding short-term risk, MBOT is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check BIO's competition here
Masimo Corporation (NASDAQ: MASI)
MBOT vs MASI Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas MASI's P/E ratio is 44.43. In terms of profitability, MBOT's ROE is -0.22%, compared to MASI's ROE of +0.09%. Regarding short-term risk, MBOT is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
MBOT vs BRKR Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, BRKR has a market cap of 8.6B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while BRKR trades at $56.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas BRKR's P/E ratio is 28.39. In terms of profitability, MBOT's ROE is -0.22%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, MBOT is more volatile compared to BRKR. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check BRKR's competition here
Bruker Corporation (NASDAQ: BRKRP)
MBOT vs BRKRP Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, BRKRP has a market cap of 8.6B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while BRKRP trades at $415.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas BRKRP's P/E ratio is 226.11. In terms of profitability, MBOT's ROE is -0.22%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, MBOT is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check BRKRP's competition here
Haemonetics Corporation (NYSE: HAE)
MBOT vs HAE Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, HAE has a market cap of 5.5B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while HAE trades at $120.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas HAE's P/E ratio is 24.01. In terms of profitability, MBOT's ROE is -0.22%, compared to HAE's ROE of +0.11%. Regarding short-term risk, MBOT is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
MBOT vs NARI Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas NARI's P/E ratio is -59.24. In terms of profitability, MBOT's ROE is -0.22%, compared to NARI's ROE of -0.00%. Regarding short-term risk, MBOT is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check NARI's competition here
LivaNova PLC (NASDAQ: LIVN)
MBOT vs LIVN Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, LIVN has a market cap of 4.4B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while LIVN trades at $79.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas LIVN's P/E ratio is 18.98. In terms of profitability, MBOT's ROE is -0.22%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, MBOT is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check LIVN's competition here
Integer Holdings Corporation (NYSE: ITGR)
MBOT vs ITGR Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while ITGR trades at $126.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas ITGR's P/E ratio is 19.94. In terms of profitability, MBOT's ROE is -0.22%, compared to ITGR's ROE of +0.06%. Regarding short-term risk, MBOT is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check ITGR's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
MBOT vs IRTC Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, IRTC has a market cap of 4.2B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while IRTC trades at $126.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas IRTC's P/E ratio is -293.88. In terms of profitability, MBOT's ROE is -0.22%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, MBOT is more volatile compared to IRTC. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check IRTC's competition here
AxoGen, Inc. (NASDAQ: AXGN)
MBOT vs AXGN Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, AXGN has a market cap of 3B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while AXGN trades at $49.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas AXGN's P/E ratio is 130.34. In terms of profitability, MBOT's ROE is -0.22%, compared to AXGN's ROE of -0.11%. Regarding short-term risk, MBOT is more volatile compared to AXGN. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check AXGN's competition here
Neogen Corporation (NASDAQ: NEOG)
MBOT vs NEOG Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, NEOG has a market cap of 2.6B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while NEOG trades at $12.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas NEOG's P/E ratio is 42.21. In terms of profitability, MBOT's ROE is -0.22%, compared to NEOG's ROE of -0.03%. Regarding short-term risk, MBOT is more volatile compared to NEOG. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check NEOG's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
MBOT vs TMDX Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, TMDX has a market cap of 2.3B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while TMDX trades at $67.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas TMDX's P/E ratio is 34.18. In terms of profitability, MBOT's ROE is -0.22%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, MBOT is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check TMDX's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
MBOT vs UFPT Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, UFPT has a market cap of 2.2B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while UFPT trades at $280.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas UFPT's P/E ratio is 28.63. In terms of profitability, MBOT's ROE is -0.22%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, MBOT is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check UFPT's competition here
NuVasive, Inc. (NASDAQ: NUVA)
MBOT vs NUVA Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas NUVA's P/E ratio is 75.00. In terms of profitability, MBOT's ROE is -0.22%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, MBOT is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check NUVA's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
MBOT vs ESTA Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, ESTA has a market cap of 1.8B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while ESTA trades at $61.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas ESTA's P/E ratio is -48.79. In terms of profitability, MBOT's ROE is -0.22%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, MBOT is more volatile compared to ESTA. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check ESTA's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
MBOT vs INSP Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, INSP has a market cap of 1.8B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while INSP trades at $61.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas INSP's P/E ratio is 27.21. In terms of profitability, MBOT's ROE is -0.22%, compared to INSP's ROE of +0.12%. Regarding short-term risk, MBOT is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for MBOT.Check INSP's competition here
Butterfly Network, Inc. (NYSE: BFLY)
MBOT vs BFLY Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, BFLY has a market cap of 1.7B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while BFLY trades at $6.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas BFLY's P/E ratio is -26.71. In terms of profitability, MBOT's ROE is -0.22%, compared to BFLY's ROE of -0.28%. Regarding short-term risk, MBOT is more volatile compared to BFLY. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check BFLY's competition here
Novocure Ltd (NASDAQ: NVCR)
MBOT vs NVCR Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, NVCR has a market cap of 1.5B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while NVCR trades at $13.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas NVCR's P/E ratio is -12.45. In terms of profitability, MBOT's ROE is -0.22%, compared to NVCR's ROE of -0.36%. Regarding short-term risk, MBOT is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check NVCR's competition here
CONMED Corporation (NYSE: CNMD)
MBOT vs CNMD Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while CNMD trades at $47.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas CNMD's P/E ratio is 10.39. In terms of profitability, MBOT's ROE is -0.22%, compared to CNMD's ROE of +0.07%. Regarding short-term risk, MBOT is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check CNMD's competition here
Heska Corporation (NASDAQ: HSKA)
MBOT vs HSKA Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas HSKA's P/E ratio is -62.49. In terms of profitability, MBOT's ROE is -0.22%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, MBOT is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check HSKA's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
MBOT vs TNDM Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, TNDM has a market cap of 1.2B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while TNDM trades at $17.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas TNDM's P/E ratio is -18.98. In terms of profitability, MBOT's ROE is -0.22%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, MBOT is more volatile compared to TNDM. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check TNDM's competition here
Enovis Corporation (NYSE: ENOV)
MBOT vs ENOV Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, ENOV has a market cap of 1.2B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while ENOV trades at $20.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas ENOV's P/E ratio is 5.98. In terms of profitability, MBOT's ROE is -0.22%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, MBOT is more volatile compared to ENOV. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check ENOV's competition here
Avanos Medical, Inc. (NYSE: AVNS)
MBOT vs AVNS Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas AVNS's P/E ratio is 27.77. In terms of profitability, MBOT's ROE is -0.22%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, MBOT is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check AVNS's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
MBOT vs ATEC Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, ATEC has a market cap of 1.2B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while ATEC trades at $7.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas ATEC's P/E ratio is -13.28. In terms of profitability, MBOT's ROE is -0.22%, compared to ATEC's ROE of -5.47%. Regarding short-term risk, MBOT is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for MBOT.Check ATEC's competition here
Artivion, Inc. (NYSE: AORT)
MBOT vs AORT Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, AORT has a market cap of 1.2B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while AORT trades at $23.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas AORT's P/E ratio is 39.53. In terms of profitability, MBOT's ROE is -0.22%, compared to AORT's ROE of -0.01%. Regarding short-term risk, MBOT is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check AORT's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
MBOT vs PRCT Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, PRCT has a market cap of 1.1B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while PRCT trades at $20.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas PRCT's P/E ratio is -10.40. In terms of profitability, MBOT's ROE is -0.22%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, MBOT is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for MBOT.Check PRCT's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
MBOT vs SILK Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas SILK's P/E ratio is -18.96. In terms of profitability, MBOT's ROE is -0.22%, compared to SILK's ROE of -0.35%. Regarding short-term risk, MBOT is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check SILK's competition here
Paragon 28, Inc. (NYSE: FNA)
MBOT vs FNA Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas FNA's P/E ratio is -19.83. In terms of profitability, MBOT's ROE is -0.22%, compared to FNA's ROE of -0.35%. Regarding short-term risk, MBOT is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check FNA's competition here
CeriBell, Inc. (NASDAQ: CBLL)
MBOT vs CBLL Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, CBLL has a market cap of 1.1B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while CBLL trades at $28.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas CBLL's P/E ratio is -16.06. In terms of profitability, MBOT's ROE is -0.22%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, MBOT is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for MBOT.Check CBLL's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
MBOT vs LMRI Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while LMRI trades at $11.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas LMRI's P/E ratio is -21.85. In terms of profitability, MBOT's ROE is -0.22%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, MBOT is more volatile compared to LMRI. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check LMRI's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
MBOT vs SIBN Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, SIBN has a market cap of 1.1B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while SIBN trades at $23.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas SIBN's P/E ratio is -69.91. In terms of profitability, MBOT's ROE is -0.22%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, MBOT is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for MBOT.Check SIBN's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
MBOT vs IART Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, IART has a market cap of 1.1B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while IART trades at $13.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas IART's P/E ratio is 5.78. In terms of profitability, MBOT's ROE is -0.22%, compared to IART's ROE of +0.01%. Regarding short-term risk, MBOT is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check IART's competition here
IRadimed Corporation (NASDAQ: IRMD)
MBOT vs IRMD Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, IRMD has a market cap of 1B. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while IRMD trades at $81.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas IRMD's P/E ratio is 40.79. In terms of profitability, MBOT's ROE is -0.22%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, MBOT is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check IRMD's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
MBOT vs AHCO Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, AHCO has a market cap of 856.2M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while AHCO trades at $6.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas AHCO's P/E ratio is 12.82. In terms of profitability, MBOT's ROE is -0.22%, compared to AHCO's ROE of -0.29%. Regarding short-term risk, MBOT is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for MBOT.Check AHCO's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
MBOT vs CSII Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas CSII's P/E ratio is -20.83. In terms of profitability, MBOT's ROE is -0.22%, compared to CSII's ROE of -0.14%. Regarding short-term risk, MBOT is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check CSII's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
MBOT vs KIDS Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, KIDS has a market cap of 820.1M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while KIDS trades at $31.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas KIDS's P/E ratio is -23.44. In terms of profitability, MBOT's ROE is -0.22%, compared to KIDS's ROE of -0.10%. Regarding short-term risk, MBOT is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check KIDS's competition here
InMode Ltd. (NASDAQ: INMD)
MBOT vs INMD Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, INMD has a market cap of 810.2M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while INMD trades at $14.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas INMD's P/E ratio is 9.78. In terms of profitability, MBOT's ROE is -0.22%, compared to INMD's ROE of +0.12%. Regarding short-term risk, MBOT is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check INMD's competition here
Varex Imaging Corporation (NASDAQ: VREX)
MBOT vs VREX Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, VREX has a market cap of 786.8M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while VREX trades at $18.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas VREX's P/E ratio is 19.51. In terms of profitability, MBOT's ROE is -0.22%, compared to VREX's ROE of +0.05%. Regarding short-term risk, MBOT is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check VREX's competition here
Picard Medical, Inc. (AMEX: PMI)
MBOT vs PMI Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, PMI has a market cap of 784.6M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while PMI trades at $7.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas PMI's P/E ratio is -6.37. In terms of profitability, MBOT's ROE is -0.22%, compared to PMI's ROE of -9.31%. Regarding short-term risk, MBOT is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for MBOT.Check PMI's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
MBOT vs CTKB Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, CTKB has a market cap of 776M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while CTKB trades at $5.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas CTKB's P/E ratio is -31.63. In terms of profitability, MBOT's ROE is -0.22%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, MBOT is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check CTKB's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
MBOT vs PACB Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, PACB has a market cap of 758.4M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while PACB trades at $2.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas PACB's P/E ratio is -5.95. In terms of profitability, MBOT's ROE is -0.22%, compared to PACB's ROE of -49.62%. Regarding short-term risk, MBOT is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for MBOT.Check PACB's competition here
Bioventus Inc. (NASDAQ: BVS)
MBOT vs BVS Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, BVS has a market cap of 747.6M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while BVS trades at $10.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas BVS's P/E ratio is 14.40. In terms of profitability, MBOT's ROE is -0.22%, compared to BVS's ROE of +0.27%. Regarding short-term risk, MBOT is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for MBOT.Check BVS's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
MBOT vs BBNX Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, BBNX has a market cap of 679.8M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while BBNX trades at $15.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas BBNX's P/E ratio is -8.21. In terms of profitability, MBOT's ROE is -0.22%, compared to BBNX's ROE of -0.27%. Regarding short-term risk, MBOT is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for MBOT.Check BBNX's competition here
Surmodics, Inc. (NASDAQ: SRDX)
MBOT vs SRDX Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas SRDX's P/E ratio is -34.66. In terms of profitability, MBOT's ROE is -0.22%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, MBOT is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check SRDX's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
MBOT vs APEN Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas APEN's P/E ratio is -9.43. In terms of profitability, MBOT's ROE is -0.22%, compared to APEN's ROE of -0.85%. Regarding short-term risk, MBOT is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check APEN's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
MBOT vs TCMD Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, TCMD has a market cap of 561.3M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while TCMD trades at $24.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas TCMD's P/E ratio is 22.94. In terms of profitability, MBOT's ROE is -0.22%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, MBOT is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for MBOT.Check TCMD's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
MBOT vs AVR Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, AVR has a market cap of 545.8M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while AVR trades at $5.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas AVR's P/E ratio is -2.89. In terms of profitability, MBOT's ROE is -0.22%, compared to AVR's ROE of -0.78%. Regarding short-term risk, MBOT is more volatile compared to AVR. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check AVR's competition here
ZimVie Inc. (NASDAQ: ZIMV)
MBOT vs ZIMV Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, MBOT's ROE is -0.22%, compared to ZIMV's ROE of -0.07%. Regarding short-term risk, MBOT is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check ZIMV's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
MBOT vs SGHT Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, SGHT has a market cap of 518.9M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while SGHT trades at $9.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas SGHT's P/E ratio is -16.82. In terms of profitability, MBOT's ROE is -0.22%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, MBOT is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for MBOT.Check SGHT's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
MBOT vs DCTH Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, DCTH has a market cap of 499.7M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while DCTH trades at $14.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas DCTH's P/E ratio is 1440.00. In terms of profitability, MBOT's ROE is -0.22%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, MBOT is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check DCTH's competition here
Cerus Corporation (NASDAQ: CERS)
MBOT vs CERS Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, CERS has a market cap of 470.6M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while CERS trades at $2.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas CERS's P/E ratio is -77.57. In terms of profitability, MBOT's ROE is -0.22%, compared to CERS's ROE of -0.11%. Regarding short-term risk, MBOT is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for MBOT.Check CERS's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
MBOT vs SENS Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, SENS has a market cap of 468.5M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while SENS trades at $8.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas SENS's P/E ratio is -3.97. In terms of profitability, MBOT's ROE is -0.22%, compared to SENS's ROE of -1.66%. Regarding short-term risk, MBOT is more volatile compared to SENS. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check SENS's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
MBOT vs SSII Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, SSII has a market cap of 459.1M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while SSII trades at $2.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas SSII's P/E ratio is -38.17. In terms of profitability, MBOT's ROE is -0.22%, compared to SSII's ROE of -0.27%. Regarding short-term risk, MBOT is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for MBOT.Check SSII's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
MBOT vs NPCE Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, NPCE has a market cap of 423.6M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while NPCE trades at $12.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas NPCE's P/E ratio is -21.65. In terms of profitability, MBOT's ROE is -0.22%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, MBOT is more volatile compared to NPCE. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check NPCE's competition here
Avita Medical Inc. (NASDAQ: RCEL)
MBOT vs RCEL Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, RCEL has a market cap of 380.8M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while RCEL trades at $15.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas RCEL's P/E ratio is -10.65. In terms of profitability, MBOT's ROE is -0.22%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, MBOT is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for MBOT.Check RCEL's competition here
CapsoVision, Inc. (NASDAQ: CV)
MBOT vs CV Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, CV has a market cap of 356.5M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while CV trades at $6.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas CV's P/E ratio is -10.63. In terms of profitability, MBOT's ROE is -0.22%, compared to CV's ROE of -1.78%. Regarding short-term risk, MBOT is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for MBOT.Check CV's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
MBOT vs OFIX Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, OFIX has a market cap of 354.1M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while OFIX trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas OFIX's P/E ratio is -5.70. In terms of profitability, MBOT's ROE is -0.22%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, MBOT is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check OFIX's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
MBOT vs CLPT Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, CLPT has a market cap of 311.2M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while CLPT trades at $9.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas CLPT's P/E ratio is -8.23. In terms of profitability, MBOT's ROE is -0.22%, compared to CLPT's ROE of -1.70%. Regarding short-term risk, MBOT is more volatile compared to CLPT. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check CLPT's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
MBOT vs SMLR Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas SMLR's P/E ratio is 3.92. In terms of profitability, MBOT's ROE is -0.22%, compared to SMLR's ROE of +0.20%. Regarding short-term risk, MBOT is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
MBOT vs TMCI Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, TMCI has a market cap of 278.3M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while TMCI trades at $4.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas TMCI's P/E ratio is -4.55. In terms of profitability, MBOT's ROE is -0.22%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, MBOT is more volatile compared to TMCI. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check TMCI's competition here
Quantum-Si incorporated (NASDAQ: QSI)
MBOT vs QSI Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, QSI has a market cap of 258.6M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while QSI trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas QSI's P/E ratio is -2.83. In terms of profitability, MBOT's ROE is -0.22%, compared to QSI's ROE of -0.47%. Regarding short-term risk, MBOT is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for MBOT.Check QSI's competition here
Profound Medical Corp. (NASDAQ: PROF)
MBOT vs PROF Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, PROF has a market cap of 255.4M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while PROF trades at $6.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas PROF's P/E ratio is -7.13. In terms of profitability, MBOT's ROE is -0.22%, compared to PROF's ROE of -0.56%. Regarding short-term risk, MBOT is more volatile compared to PROF. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check PROF's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
MBOT vs INFU Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, INFU has a market cap of 252.7M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while INFU trades at $12.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas INFU's P/E ratio is 30.95. In terms of profitability, MBOT's ROE is -0.22%, compared to INFU's ROE of +0.15%. Regarding short-term risk, MBOT is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for MBOT.Check INFU's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
MBOT vs MGRM Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas MGRM's P/E ratio is -12.00. In terms of profitability, MBOT's ROE is -0.22%, compared to MGRM's ROE of -1.17%. Regarding short-term risk, MBOT is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check MGRM's competition here
Nevro Corp. (NYSE: NVRO)
MBOT vs NVRO Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas NVRO's P/E ratio is -1.91. In terms of profitability, MBOT's ROE is -0.22%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, MBOT is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check NVRO's competition here
Electromed, Inc. (AMEX: ELMD)
MBOT vs ELMD Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, ELMD has a market cap of 222M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while ELMD trades at $26.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas ELMD's P/E ratio is 20.45. In terms of profitability, MBOT's ROE is -0.22%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, MBOT is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check ELMD's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
MBOT vs TLSI Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, TLSI has a market cap of 214.3M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while TLSI trades at $3.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas TLSI's P/E ratio is -2.07. In terms of profitability, MBOT's ROE is -0.22%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, MBOT is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for MBOT.Check TLSI's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
MBOT vs BSGM Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas BSGM's P/E ratio is -5.81. In terms of profitability, MBOT's ROE is -0.22%, compared to BSGM's ROE of +6.96%. Regarding short-term risk, MBOT is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for MBOT.Check BSGM's competition here
RxSight, Inc. (NASDAQ: RXST)
MBOT vs RXST Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, RXST has a market cap of 190.9M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while RXST trades at $4.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas RXST's P/E ratio is -4.06. In terms of profitability, MBOT's ROE is -0.22%, compared to RXST's ROE of -0.17%. Regarding short-term risk, MBOT is more volatile compared to RXST. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check RXST's competition here
Inogen, Inc. (NASDAQ: INGN)
MBOT vs INGN Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, INGN has a market cap of 186.6M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while INGN trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas INGN's P/E ratio is -7.73. In terms of profitability, MBOT's ROE is -0.22%, compared to INGN's ROE of -0.13%. Regarding short-term risk, MBOT is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check INGN's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
MBOT vs MDGS Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas MDGS's P/E ratio is -0.27. In terms of profitability, MBOT's ROE is -0.22%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, MBOT is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for MBOT.Check MDGS's competition here
Neuronetics, Inc. (NASDAQ: STIM)
MBOT vs STIM Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, STIM has a market cap of 172.2M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while STIM trades at $2.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas STIM's P/E ratio is -5.14. In terms of profitability, MBOT's ROE is -0.22%, compared to STIM's ROE of -1.51%. Regarding short-term risk, MBOT is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for MBOT.Check STIM's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
MBOT vs QIPT Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas QIPT's P/E ratio is -15.87. In terms of profitability, MBOT's ROE is -0.22%, compared to QIPT's ROE of -0.08%. Regarding short-term risk, MBOT is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check QIPT's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
MBOT vs FOCL Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, FOCL has a market cap of 157.4M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while FOCL trades at $4.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas FOCL's P/E ratio is -4.06. In terms of profitability, MBOT's ROE is -0.22%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, MBOT is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for MBOT.Check FOCL's competition here
Quanterix Corporation (NASDAQ: QTRX)
MBOT vs QTRX Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, QTRX has a market cap of 139M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while QTRX trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas QTRX's P/E ratio is -1.16. In terms of profitability, MBOT's ROE is -0.22%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, MBOT is more volatile compared to QTRX. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check QTRX's competition here
Owlet, Inc. (NYSE: OWLT)
MBOT vs OWLT Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, OWLT has a market cap of 123.6M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while OWLT trades at $4.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas OWLT's P/E ratio is -30.21. In terms of profitability, MBOT's ROE is -0.22%, compared to OWLT's ROE of -0.50%. Regarding short-term risk, MBOT is more volatile compared to OWLT. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check OWLT's competition here
Pulmonx Corporation (NASDAQ: LUNG)
MBOT vs LUNG Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, LUNG has a market cap of 116.8M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while LUNG trades at $2.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas LUNG's P/E ratio is -2.69. In terms of profitability, MBOT's ROE is -0.22%, compared to LUNG's ROE of -0.98%. Regarding short-term risk, MBOT is less volatile compared to LUNG. This indicates lower risk in terms of short-term price fluctuations for MBOT.Check LUNG's competition here
iCAD, Inc. (NASDAQ: ICAD)
MBOT vs ICAD Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas ICAD's P/E ratio is -20.37. In terms of profitability, MBOT's ROE is -0.22%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, MBOT is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check ICAD's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
MBOT vs CATX Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, CATX has a market cap of 100M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while CATX trades at $0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas CATX's P/E ratio is -0.66. In terms of profitability, MBOT's ROE is -0.22%, compared to CATX's ROE of -0.42%. Regarding short-term risk, MBOT is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for MBOT.Check CATX's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
MBOT vs HJLI Comparison November 2026
Microbot Medical Inc. (NASDAQ: MBOT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MBOT stands at 73.2M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, MBOT is priced at $1.09 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MBOT currently has a P/E ratio of -4.54, whereas HJLI's P/E ratio is N/A. In terms of profitability, MBOT's ROE is -0.22%, compared to HJLI's ROE of -0.70%. Regarding short-term risk, MBOT is more volatile compared to HJLI. This indicates higher risk in terms of short-term price fluctuations for MBOT.Check HJLI's competition here